Krystal Biotech Rises as Investors Lean on Commercial Momentum and Pipeline Catalysts

Krystal Biotech (KRYS) is up 5.9% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear same-day catalyst is not obvious, but the move appears tied to continued confidence in Krystal Biotech’s commercial execution and late-stage pipeline. This could also be because investors are positioning ahead of multiple 2026 data readouts, while a recent bullish analyst target increase added to momentum.

Details:

Krystal Biotech’s first-quarter 2026 update showed VYJUVEK global revenue of $116.4 million, up 32% from a year earlier, alongside strong profitability and about $1.0 billion in cash and investments.

The company said its KB803 registrational study is fully enrolled and that both KB803 and KB801 are still on track for registrational data readouts in 2026, giving the stock meaningful near-term clinical catalysts.

In May, the company announced United Kingdom approval for VYJUVEK, expanding its commercial footprint and adding another regulatory win for its lead product.

A recent Jefferies note raised its price target on KRYS to $371 from $310 after meetings with management, highlighting re-accelerating U.S. demand, growing international opportunity, and a maturing pipeline.

Sources:

Krystal Biotech, TipRanks, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$KRYS Insider Trading Activity

$KRYS insiders have traded $KRYS stock on the open market 76 times in the past 6 months. Of those trades, 0 have been purchases and 76 have been sales.

Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:

DANIEL JANNEY has made 0 purchases and 22 sales selling 71,964 shares for an estimated $19,402,207.
SUMA KRISHNAN (President, R&D) has made 0 purchases and 21 sales selling 50,000 shares for an estimated $14,283,095.
KRISH S KRISHNAN (President and CEO) has made 0 purchases and 21 sales selling 50,000 shares for an estimated $14,282,148.
DINO A ROSSI has made 0 purchases and 2 sales selling 18,950 shares for an estimated $4,953,694.
KATHRYN ROMANO (Chief Accounting Officer) has made 0 purchases and 8 sales selling 13,250 shares for an estimated $3,602,405.
JOHN CHARLES THOMAS (EVP, General Counsel) has made 0 purchases and 2 sales selling 1,642 shares for an estimated $541,173.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive KRYS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$KRYS Hedge Fund Activity

We have seen 189 institutional investors add shares of $KRYS stock to their portfolio, and 123 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC removed 383,779 shares (-99.3%) from their portfolio in Q1 2026, for an estimated $99,137,791
SOLEUS CAPITAL MANAGEMENT, L.P. added 212,028 shares (+22.5%) to their portfolio in Q1 2026, for an estimated $54,771,072
MARSHALL WACE, LLP removed 115,411 shares (-62.8%) from their portfolio in Q1 2026, for an estimated $29,812,969
FIRST TRUST ADVISORS LP added 105,245 shares (+42.9%) to their portfolio in Q1 2026, for an estimated $27,186,888
RAYMOND JAMES FINANCIAL INC added 79,526 shares (+103.9%) to their portfolio in Q1 2026, for an estimated $20,543,156
GOLDMAN SACHS GROUP INC removed 78,576 shares (-26.8%) from their portfolio in Q1 2026, for an estimated $20,297,752
BELLEVUE GROUP AG added 71,462 shares (+17.4%) to their portfolio in Q1 2026, for an estimated $18,460,063

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$KRYS Analyst Ratings

Wall Street analysts have issued reports on $KRYS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/22/2026

To track analyst ratings and price targets for $KRYS, check out Quiver Quantitative's $KRYS forecast page.

$KRYS Price Targets

Multiple analysts have issued price targets for $KRYS recently. We have seen 9 analysts offer price targets for $KRYS in the last 6 months, with a median target of $327.0.

Here are some recent targets:

Ritu Baral from TD Cowen set a target price of $403.0 on 06/18/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $361.0 on 06/16/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $300.0 on 05/05/2026
Yigal Nochomovitz from Citigroup set a target price of $378.0 on 05/05/2026
Debjit Chattopadhyay from Guggenheim set a target price of $284.0 on 02/25/2026
Geulah Livshits from Chardan Capital set a target price of $323.0 on 02/18/2026
Roger Song from Jefferies set a target price of $371.0 on 02/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.